| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Immunology |
Department of Biological Sciences, University of Maryland Baltimore County, Baltimore, Maryland 21250 [B. A. P., E. M., S. O-R.]; Enerjen, Carmel, California 93921 [D. S. T.]; and Department of Molecular Genetics and Biochemistry, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15261 [S. K.]
One of the leading causes of death for women is metastatic breast cancer. Because most animal tumors do not accurately model clinical metastatic disease, the development of effective therapies has progressed slowly. In this study, we establish the poorly immunogenic mouse 4T1 mammary carcinoma as a postsurgical animal model. 4T1 growth characteristics parallel highly invasive human metastatic mammary carcinoma and, at the time of surgery, the extent of disease is comparable with human stage IV breast cancer. Progress in understanding the immune response has led to innovative immune-based anticancer therapies. Here, we test in this postsurgical model, a novel cell-based vaccine, combining MHC class II, CD80 (B7.1), and SEB superantigen. Effective treatment of tumor-bearing mice with this immunotherapy requires expression of all three molecules. Mean survival time is extended from 5–7.5 weeks for control-treated mice to 6–10.5 weeks for therapy-treated mice. Increased survival is accompanied by a maximum of 100-fold decrease in clonogenic lung metastases. These therapeutic effects are particularly noteworthy because: (a) the postoperative model demonstrates that early metastases responsible for morbidity are established by 2 weeks after tumor inoculation with 7 x 103 parental 4T1 cells into the mammary gland; (b) the immunotherapy is started 4 weeks after tumor inoculation when the mice contain extensive, pre-established, disseminated metastases; and (c) CD4+ and CD8+ T cells are required for the effect.
This article has been cited by other articles:
|
|
 |
|
  X. Ling, M. Konopleva, Z. Zeng, V. Ruvolo, L. C. Stephens, W. Schober, T. McQueen, M. Dietrich, T. L. Madden, and M. Andreeff The Novel Triterpenoid C-28 Methyl Ester of 2-Cyano-3, 12-Dioxoolen-1, 9-Dien-28-Oic Acid Inhibits Metastatic Murine Breast Tumor Growth through Inactivation of STAT3 Signaling Cancer Res., May 1, 2007; 67(9): 4210 - 4218. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Yang, Y. Chu, Y. Wang, R. Zhang, and S. Xiong Targeted in vivo expression of IFN-{gamma}-inducible protein 10 induces specific antitumor activity J. Leukoc. Biol., December 1, 2006; 80(6): 1434 - 1444. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Thompson, S. K. Dissanayake, B. R. Ksander, K. L. Knutson, M. L. Disis, and S. Ostrand-Rosenberg Tumor Cells Transduced with the MHC Class II Transactivator and CD80 Activate Tumor-Specific CD4+ T Cells Whether or Not They Are Silenced for Invariant Chain Cancer Res., January 15, 2006; 66(2): 1147 - 1154. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Norton, M. Li, N. C. Lee, and K. Tsung Inhibition of Host Signal Transducer and Activator of Transcription Factor 6 Results in Cure With Cyclophosphamide and Interleukin 12 Immunotherapy Ann. Surg. Oncol., January 1, 2006; 13(1): 118 - 124. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. N. Torrero, W. G. Henk, and S. Li Regression of High-Grade Malignancy in Mice by Bleomycin and Interleukin-12 Electrochemogenetherapy Clin. Cancer Res., January 1, 2006; 12(1): 257 - 263. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Sinha, V. K. Clements, and S. Ostrand-Rosenberg Interleukin-13-regulated M2 Macrophages in Combination with Myeloid Suppressor Cells Block Immune Surveillance against Metastasis Cancer Res., December 15, 2005; 65(24): 11743 - 11751. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Ling and R. B. Arlinghaus Knockdown of STAT3 Expression by RNA Interference Inhibits the Induction of Breast Tumors in Immunocompetent Mice Cancer Res., April 1, 2005; 65(7): 2532 - 2536. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. D. Lewis, M. H. Shearer, R. C. Kennedy, and R. K. Bright Surrogate Tumor Antigen Vaccination Induces Tumor-Specific Immunity and the Rejection of Spontaneous Metastases Cancer Res., April 1, 2005; 65(7): 2938 - 2946. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. K. Dissanayake, N. Tuera, and S. Ostrand-Rosenberg Presentation of Endogenously Synthesized MHC Class II-Restricted Epitopes by MHC Class II Cancer Vaccines Is Independent of Transporter Associated with Ag Processing and the Proteasome J. Immunol., February 15, 2005; 174(4): 1811 - 1819. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Demaria, N. Kawashima, A. M. Yang, M. L. Devitt, J. S. Babb, J. P. Allison, and S. C. Formenti Immune-Mediated Inhibition of Metastases after Treatment with Local Radiation and CTLA-4 Blockade in a Mouse Model of Breast Cancer Clin. Cancer Res., January 15, 2005; 11(2): 728 - 734. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. C. P. Smith, K. E. Luker, J. R. Garbow, J. L. Prior, E. Jackson, D. Piwnica-Worms, and G. D. Luker CXCR4 Regulates Growth of Both Primary and Metastatic Breast Cancer Cancer Res., December 1, 2004; 64(23): 8604 - 8612. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Ren, D. S. Terman, G. Bohach, A. Silvers, C. Hansen, H. Colt, and S. A. Sahn Intrapleural Staphylococcal Superantigen Induces Resolution of Malignant Pleural Effusions and a Survival Benefit in Non-Small Cell Lung Cancer Chest, November 1, 2004; 126(5): 1529 - 1539. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Guiducci, E. Di Carlo, M. Parenza, M. Hitt, M. Giovarelli, P. Musiani, and M. P. Colombo Intralesional Injection of Adenovirus Encoding CC Chemokine Ligand 16 Inhibits Mammary Tumor Growth and Prevents Metastatic-Induced Death after Surgical Removal of the Treated Primary Tumor J. Immunol., April 1, 2004; 172(7): 4026 - 4036. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. K. Dissanayake, J. A. Thompson, J. J. Bosch, V. K. Clements, P. W. Chen, B. R. Ksander, and S. Ostrand-Rosenberg Activation of Tumor-specific CD4+ T Lymphocytes by Major Histocompatibility Complex Class II Tumor Cell Vaccines: A Novel Cell-based Immunotherapy Cancer Res., March 1, 2004; 64(5): 1867 - 1874. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Fong, Y. Itahana, T. Sumida, J. Singh, J.-P. Coppe, Y. Liu, P. C. Richards, J. L. Bennington, N. M. Lee, R. J. Debs, et al. Id-1 as a molecular target in therapy for breast cancer cell invasion and metastasis PNAS, November 11, 2003; 100(23): 13543 - 13548. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Ostrand-Rosenberg, V. K. Clements, M. Terabe, J. M. Park, J. A. Berzofsky, and S. K. Dissanayake Resistance to Metastatic Disease in STAT6-Deficient Mice Requires Hemopoietic and Nonhemopoietic Cells and Is IFN-{gamma} Dependent J. Immunol., November 15, 2002; 169(10): 5796 - 5804. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Huang, M. K. Wong, H. Yi, S. Watkins, A. D. Laird, S. F. Wolf, and E. Gorelik Combined Therapy of Local and Metastatic 4T1 Breast Tumor in Mice Using SU6668, an Inhibitor of Angiogenic Receptor Tyrosine Kinases, and the Immunostimulator B7.2-IgG Fusion Protein Cancer Res., October 15, 2002; 62(20): 5727 - 5735. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. A. Pulaski, M. J. Smyth, and S. Ostrand-Rosenberg Interferon-{gamma}-dependent Phagocytic Cells Are a Critical Component of Innate Immunity against Metastatic Mammary Carcinoma Cancer Res., August 1, 2002; 62(15): 4406 - 4412. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Cretney, K. Takeda, H. Yagita, M. Glaccum, J. J. Peschon, and M. J. Smyth Increased Susceptibility to Tumor Initiation and Metastasis in TNF-Related Apoptosis-Inducing Ligand-Deficient Mice J. Immunol., February 1, 2002; 168(3): 1356 - 1361. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Ostrand-Rosenberg, M. J. Grusby, and V. K. Clements Cutting Edge: STAT6-Deficient Mice Have Enhanced Tumor Immunity to Primary and Metastatic Mammary Carcinoma J. Immunol., December 1, 2000; 165(11): 6015 - 6019. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Qi, J.-M. Rojas, and S. Ostrand-Rosenberg Tumor Cells Present MHC Class II-Restricted Nuclear and Mitochondrial Antigens and Are the Predominant Antigen Presenting Cells In Vivo J. Immunol., November 15, 2000; 165(10): 5451 - 5461. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
